These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31511358)

  • 1. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
    Hofland T; de Weerdt I; Ter Burg H; de Boer R; Tannheimer S; Tonino SH; Kater AP; Eldering E
    J Immunol; 2019 Oct; 203(8):2100-2109. PubMed ID: 31511358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.
    Guo A; Lu P; Coffey G; Conley P; Pandey A; Wang YL
    Oncotarget; 2017 Feb; 8(8):12953-12967. PubMed ID: 28088788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
    Spaner DE; McCaw L; Wang G; Tsui H; Shi Y
    Cancer Med; 2019 Apr; 8(4):1540-1550. PubMed ID: 30843659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
    Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
    Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to BTK inhibitors in patients with chronic lymphocytic leukemia.
    Woyach JA
    Clin Adv Hematol Oncol; 2021 Jul; 19(7):436-438. PubMed ID: 34236341
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.
    Sharif-Askari B; Doyon D; Paliouras M; Aloyz R
    Sci Rep; 2019 Jul; 9(1):11069. PubMed ID: 31363127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
    Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
    Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
    Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
    Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.
    Palma M; Mulder TA; Österborg A
    Front Immunol; 2021; 12():686768. PubMed ID: 34276674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
    Cheng S; Ma J; Guo A; Lu P; Leonard JP; Coleman M; Liu M; Buggy JJ; Furman RR; Wang YL
    Leukemia; 2014 Mar; 28(3):649-57. PubMed ID: 24270740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
    Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.